Immune cell study in muscle-invasive bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at tissue from bladder cancer surgeries to understand how immune cells and surrounding tissue interact. It may help find better ways to treat bladder cancer in the future, but it does not involve new treatments for participants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had your bladder removed because of muscle-invasive bladder cancer.
- You were treated at the South Egypt Cancer Institute between 2018 and 2024.
- Your cancer is the most common type (urothelial carcinoma) — not a rare type like squamous cell carcinoma.
- You did not receive chemotherapy or radiation before your bladder surgery.
- You have no other current or past cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tumor and blood samples from people with muscle-invasive bladder cancer to find markers that help predict how the disease will progress. It aims to improve personalized treatment for those with this specific stage of bladder cancer.
This study looks at how well a standard chemotherapy given before surgery works for muscle-invasive bladder cancer. It aims to see if higher responses lead to better outcomes.
This trial tests giving chemotherapy before surgery to remove the bladder, to see if it can improve outcomes for patients with muscle-invasive bladder cancer. The treatment is personalized based on a lab test of your tumor cells, which may help make the therapy more effective.
This trial tests whether people with muscle-invasive bladder cancer can safely avoid immediate surgery or radiation after a short course of chemotherapy. Instead, they would be closely monitored and only treated if the cancer comes back.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial studies how well certain markers in bladder cancer tissue can predict which patients will respond to chemotherapy given before surgery. This may help doctors choose the best treatment for each patient in the future.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.